Skip to main content
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
35.61
+0.77 (2.21%)
At close: May 16, 2025, 4:00 PM
35.39
-0.22 (-0.62%)
After-hours: May 16, 2025, 7:08 PM EDT

Ultragenyx Pharmaceutical Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Product
314.47M 285.47M 265.30M 230.30M 198.70M 180.40M 157.60M 147.80M
Product Growth
58.26% 58.24% 68.34% 55.82% 45.67% 51.72% 43.01% 48.24%
Other
276.21M 274.71M 257.40M 250.90M 243.80M 253.80M 252.60M 245.10M
Other Growth
13.29% 8.24% 1.90% 2.37% 2.65% 8.28% 13.27% 4.56%

Revenue by Geography
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
North America
340.46M 316.40M 307.30M 297.70M 307.10M 299.00M 298.20M 286.20M
North America Growth
10.86% 5.82% 3.05% 4.02% 9.29% 11.94% 11.69% 3.96%
Latin America
130.71M 130.30M 109.50M 89.70M 77.30M 67.40M 64.30M 57.70M
Latin America Growth
69.10% 93.32% 70.30% 55.46% 72.93% 61.24% 82.67% 110.58%
Europe
80.12M 69.60M 60.40M 54.20M 47.60M 42.70M 38.10M 37.60M
Europe Growth
68.33% 63.00% 58.53% 44.15% 30.77% 28.61% 19.06% 28.77%
Japan
- 6.40M 4.10M - 2.20M - - 2.40M
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.